Adc Discovery and Option Agreement Sample Contracts
= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND...Adc Discovery and Option Agreement • February 18th, 2025 • Glycomimetics Inc • Pharmaceutical preparations • Massachusetts
This ADC Discovery and Option Agreement (“Agreement”) is entered into and effective as of October 28, 2024 (the “Effective Date”), by and among Paragon Therapeutics, Inc., a Delaware corporation (“Paragon”), Parascent Holding LLC, a Delaware limited liability company (“Parascent”) and Crescent Biopharma, Inc., a Delaware corporation (“Crescent”). Paragon, Parascent and Crescent are also referred to herein individually as a “Party”, or collectively as the “Parties.”
ADC DISCOVERY AND OPTION AGREEMENTAdc Discovery and Option Agreement • April 29th, 2025 • Glycomimetics Inc • Pharmaceutical preparations • Massachusetts
This ADC Discovery and Option Agreement (“Agreement”) is entered into and effective as of October 28, 2024 (the “Effective Date”), by and among Paragon Therapeutics, Inc., a Delaware corporation (“Paragon”), Parascent Holding LLC, a Delaware limited liability company (“Parascent”) and Crescent Biopharma, Inc., a Delaware corporation (“Crescent”). Paragon, Parascent and Crescent are also referred to herein individually as a “Party”, or collectively as the “Parties.”
= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT BOTH CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND...Adc Discovery and Option Agreement • April 29th, 2025 • Glycomimetics Inc • Pharmaceutical preparations • Massachusetts
This Amended and Restated ADC Discovery and Option Agreement (this “Agreement”) is entered into and effective as of April 28, 2025 (the “A&R Effective Date”), by and among Paragon Therapeutics, Inc., a Delaware corporation (“Paragon”), Parascent Holding LLC, a Delaware limited liability company (“Parascent”) and Crescent Biopharma, Inc., a Delaware corporation (“Crescent”), and amends and restates in its entirety that certain ADC Discovery and Option Agreement, effective as of October 28, 2024 (the “Original Effective Date”), by and among Paragon, Parascent and Crescent (the “Original Agreement”). Paragon, Parascent and Crescent are also referred to herein individually as a “Party”, or collectively as the “Parties.”